WO2000002909A3 - Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins - Google Patents

Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins Download PDF

Info

Publication number
WO2000002909A3
WO2000002909A3 PCT/IB1999/001261 IB9901261W WO0002909A3 WO 2000002909 A3 WO2000002909 A3 WO 2000002909A3 IB 9901261 W IB9901261 W IB 9901261W WO 0002909 A3 WO0002909 A3 WO 0002909A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral envelope
viral
cytoplasmic tail
peptides derived
envelope proteins
Prior art date
Application number
PCT/IB1999/001261
Other languages
French (fr)
Other versions
WO2000002909A2 (en
Inventor
Yanina Rozenberg
W French Anderson
Original Assignee
Univ Southern California
Yanina Rozenberg
W French Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California, Yanina Rozenberg, W French Anderson filed Critical Univ Southern California
Priority to JP2000559138A priority Critical patent/JP2003533165A/en
Priority to CA002333855A priority patent/CA2333855A1/en
Priority to IL14063099A priority patent/IL140630A0/en
Priority to AU43869/99A priority patent/AU4386999A/en
Priority to EP99926703A priority patent/EP1093519A2/en
Publication of WO2000002909A2 publication Critical patent/WO2000002909A2/en
Publication of WO2000002909A3 publication Critical patent/WO2000002909A3/en
Priority to US09/756,250 priority patent/US20020058020A1/en
Priority to US10/304,494 priority patent/US20040022799A1/en
Priority to AU2003235023A priority patent/AU2003235023A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An isolated peptide comprising an amino acid sequence derived from a viral envelope protein, wherein at least a portion of the amino acid sequence is located within the cytoplasmic tail or membrane-spanning region of a viral envelope protein. Such peptides are amphiphilic in nature, provide for the destabilization of membranes, and facilitate the entry of viral particles into cells and the efficient formation of viral particles. The peptides may, in another embodiment, be attached to the viral membrane, along with a targeting polypeptide, as part of an artificial viral envelope protein.
PCT/IB1999/001261 1998-07-09 1999-07-08 Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins WO2000002909A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2000559138A JP2003533165A (en) 1998-07-09 1999-07-08 An isolated amphipathic peptide from the cytoplasmic end of the viral envelope protein
CA002333855A CA2333855A1 (en) 1998-07-09 1999-07-08 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
IL14063099A IL140630A0 (en) 1998-07-09 1999-07-08 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
AU43869/99A AU4386999A (en) 1998-07-09 1999-07-08 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
EP99926703A EP1093519A2 (en) 1998-07-09 1999-07-08 Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
US09/756,250 US20020058020A1 (en) 1999-07-08 2001-01-08 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
US10/304,494 US20040022799A1 (en) 1998-07-09 2002-11-25 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
AU2003235023A AU2003235023A1 (en) 1998-07-09 2003-08-13 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11254498A 1998-07-09 1998-07-09
US09/112,544 1998-07-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11254498A Continuation-In-Part 1998-07-09 1998-07-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/756,250 Continuation US20020058020A1 (en) 1998-07-09 2001-01-08 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins

Publications (2)

Publication Number Publication Date
WO2000002909A2 WO2000002909A2 (en) 2000-01-20
WO2000002909A3 true WO2000002909A3 (en) 2000-05-04

Family

ID=22344479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001261 WO2000002909A2 (en) 1998-07-09 1999-07-08 Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins

Country Status (6)

Country Link
EP (1) EP1093519A2 (en)
JP (1) JP2003533165A (en)
AU (2) AU4386999A (en)
CA (1) CA2333855A1 (en)
IL (1) IL140630A0 (en)
WO (1) WO2000002909A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env
WO1994011524A1 (en) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Targetable vector particles
WO1996018957A1 (en) * 1994-12-14 1996-06-20 The Trustees Of Columbia University In The City Of New York A method for predicting protein structure
WO1997033908A1 (en) * 1996-03-13 1997-09-18 Commonwealth Scientific And Industrial Research Organisation Lytic peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env
WO1994011524A1 (en) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Targetable vector particles
WO1996018957A1 (en) * 1994-12-14 1996-06-20 The Trustees Of Columbia University In The City Of New York A method for predicting protein structure
WO1997033908A1 (en) * 1996-03-13 1997-09-18 Commonwealth Scientific And Industrial Research Organisation Lytic peptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EISENBERG D AND WESSON M: "The most highly amphiphilic alpha-helices include two amino acid segments in human immunodeficiency virus glycoprotein 41", BIOPOLYMERS, vol. 29, no. 1, 1992, pages 171 - 177, XP000874043 *
JANUSZESKI M.M ET AL.,: "Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein", JOURNAL OF VIROLOGY, vol. 71, no. 5, May 1997 (1997-05-01), pages 3613 - 3619, XP002130560 *
MARTIN I ET AL.,: "Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determind by its orientation in the lipid bilayer", JOURNAL OF VIROLOGY, vol. 70, no. 1, January 1996 (1996-01-01), pages 298 - 304, XP002130559 *
RAGHEB JA AND ANDERSON WF: "pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry", JOURNAL OF VIROLOGY, vol. 68, no. 5, May 1994 (1994-05-01), pages 3220 - 3231, XP000874027 *
SABERWAL G AND NAGARAJ R: "Cell-lytic and antibacterial peptides that act by perturbing the barrier function of membranes: facets of their conformational features, structure-function correlations and membrane-perturbing abilities", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1197, no. 2, 1994, pages 109 - 131, XP000878719 *
VZOROV A.N. ET AL.,: "Assembly and release o SIV Env proteins with full-length or truncated cytoplasmic domains", VIROLOGY, vol. 221, 1996, pages 22 - 33, XP002921436 *

Also Published As

Publication number Publication date
CA2333855A1 (en) 2000-01-20
WO2000002909A2 (en) 2000-01-20
AU4386999A (en) 2000-02-01
AU2003235023A1 (en) 2003-09-11
EP1093519A2 (en) 2001-04-25
JP2003533165A (en) 2003-11-11
IL140630A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
WO2002014525A3 (en) Expression vector using for animal cell
CA2089094A1 (en) Expression of recombinant polypeptides with improved purification
EP1304382A3 (en) Production of peptides in plants as viral coat protein fusions
WO2001021796A3 (en) Gl50 molecules and uses therefor
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
ES2147558T3 (en) NEW POLYPEPTIDES TO PROMOTE CELL FIXATION.
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
WO2000034474A3 (en) Growth factor homolog zvegf3
WO1999013818A3 (en) Membrane virus host range mutations and their uses as vaccine substrates
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO2000002909A3 (en) Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
AU5776799A (en) Modified hcv peptide vaccines
Vincentz et al. HMG-like protein in barley and corn nuclei
AU2957099A (en) Novel physiologically active peptides and utilization thereof
Isobe et al. Primary structure determination of mono‐and diacylglycerol lipase from Penicillium camembertii
Simons et al. Alphavirus proteins
WO1997003198A3 (en) Nucleotide and amino acid sequence and uses thereof
CA2163805A1 (en) Novel activating factor of leukocytes
EP1900816A3 (en) GL50 molecules and uses therefor
WO2001096400A3 (en) 52871, a novel human g protein coupled receptor and uses thereof
WO2000018923A3 (en) Slgp protein and nucleic acid molecule and uses therefor
WO2001090146A3 (en) 57256 and 58289, human transporters and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 140630

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 43869/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 509234

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2333855

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09756250

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 559138

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999926703

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999926703

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999926703

Country of ref document: EP